Results 141 to 150 of about 655,557 (182)

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy. [PDF]

Eur J Haematol
Oliva S, Molica S.
europepmc   +1 more source

Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study. [PDF]

Ann Hematol
Lv Y, Zhu Y, Yang C, Zhang X, Zhang X, Wei J, Ye X, Xu G, Mao L, Mai W, Yang M, Qian J, Tong H, Jin J, Yu W.   +14 more
europepmc   +1 more source

Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.

Blood, 2023
Thompson PA, Tam CS.
europepmc   +1 more source

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy. [PDF]

Leuk Lymphoma
Gruessner C, Wiestner A, Sun C.
europepmc   +1 more source

Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL. [PDF]

Mater Today Bio
Sun R, Yang Y, Zhang B, Chen J, Wang Y, Jiang Z, Zhang L, Ashrafizadeh M, Sethi G, Shen J, Chi Z.   +10 more
europepmc   +1 more source

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.

Blood, 2023
Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W, Lippincott I, Ku KS, Walgren RA, Abada PB, Ballard JA, Allerston CK, Brandhuber BJ.   +17 more
europepmc   +1 more source

Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. [PDF]

Front Immunol
Wang J, Cui R, Qi Y, Mu J, Li X, Li Q, Deng Q.   +6 more
europepmc   +1 more source

PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy. [PDF]

Proc Natl Acad Sci U S A
Chang A, Pelletier AN, McGuire DJ, Tsagiopoulou M, Karipidou M, Ayers A, Leal AMK, Churnetski MC, O'Leary CB, Switchenko JM, Davis C, Frank DA, Koff JL, Cohen JB, Sekaly RP, Stamatopoulos K, Flowers CR, Ahmed R.   +17 more
europepmc   +1 more source

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis. [PDF]

Drugs R D
Turner TJ, Brun P, Gruber RC, Ofengeim D.   +3 more
europepmc   +1 more source

Strongyloides stercoralis infection in a DLBCL patient treated with rituximab and BTK inhibitor: A case report and literature review. [PDF]

Medicine (Baltimore)
Liu W, Wang Z, Wu H, Zeng L, Cai N, Zhuang W, Guo J.   +6 more
europepmc   +1 more source